Member Info for Umaz

I tend to agreed Gareth! I think settlement is the logical way for them.

Panman.. they look quiet decent to me.

https://www.curtis.com/experience/practice-areas/commercial-disputes-arbitration/overview

Ajmalkhuram, ICC1 decision was in Dec 2024, no?

Also I doubt anything that is said on this bb affects the sp lol

--------

Exactly Jay, just bought a few more. This is one share I am confident where no immediate placing is coming. With CEO having a big stake, arbitration already decided in our favour and accumulating interest, there is little downside but far greater upside. Holding for the gold.

But as you said, anything that is said on this bb doesn't affects the sp (unless its Fonzi99) :-) so my positive comments are for me only.

This deal has elements of both potential upside and significant risk, making it a controversial financing method. Here’s a breakdown of the key factors:

Potential Benefits for ImmuPharma:

Immediate Funding: The company secures £2.91m, with £1.875m coming from Lanstead.

Potential Upside: If ImmuPharma’s share price exceeds the benchmark price (5p) over the 7-month period, the company could receive more than the pledged amount.

Fixed Share Dilution: Unlike convertible loan notes, the number of issued shares is fixed upfront.

Extended Cash Runway: The company suggests it will be funded until at least the end of 2026, assuming share price performance aligns with expectations.

Potential Risks (Possible "Death Spiral" Scenario):

Downside Exposure: If the share price drops below the 5p benchmark price, the company receives less than the pledged £1.875m, potentially creating a cash shortfall.

Dilution: Lanstead will own around 10.7% of the company, and the new shares increase the total share count significantly.

Market Impact: Lanstead’s model involves selling shares into the market over time to realise returns, which could depress the share price, leading to a self-fulfilling decline.

Past Performance: Previous Lanstead deals in 2019, 2020, 2021, and 2022 resulted in losses of £0.9m to £1.7m for ImmuPharma, suggesting this structure has historically not favoured the company.

If ImmuPharma delivers strong news flow and its share price rises above 5p, this could be a reasonable funding method. However, if the share price stagnates or declines, the company will receive less funding than expected, potentially requiring further capital raises, exacerbating dilution and investor confidence issues.

Lets see how much further does it fell than the last placing price.

Looks big selling to me. 50m shares sold at 0.145 (£72k).

Easy £10k by just selling 50m shares for 0.145 if you are guaranteed the same shares at placing price of 0.125. AIM games.

Intelligent buying at these levels.

TheFatRat, 6.5 really gone. Can buy for 6.4 :-) Good pumping !

And here comes the dump? 2 big sells?

Already close to 9.8p in Oslo (1.37NOK).

Doesn't seem to be 20% difference like last time.

Once warrants of 2p executed, will it need to be RNS'd? Wondering if these are the 2p warrants forward sold at 5p :-)

News leak - for sure.

How wrong can the charts be @ msuk. Charts pointed to 3.9p?

Jordie, hold if you can, its a paper loss until sold. Or sell, make profits elsewhere and buy back. If you are lucky, it may still be at these levels next week :-)

Funny how small buys just move the price up. All the best to the holders, but I dont think it will continue. Friday sell off I am afraid.

I believe the company will save cash for enforcement efforts unless ETAP pays. Decision of the second case is not due soon, so if I was running the company, I will keep my pockets full. Dividends may come but not in the near future.

Unless they settle, in which case the size of the dividends will be perhaps smaller.

I doubt Weardale will go for a listing in the near future. Not atleast until the design phase with KBR is completed, perhaps by Q2 this year. If Weardale are expecting the first battery-grade lithium carbonate by early 2026, then they would already have some commitments from private investors, either by MAC themselves or through MAC (being financial advisors).

Weardale Lithium, a private company, was incorporated in 2020. Mr Mark Christopher Tellwright holds 50% or more of Weardale Lithium. For Marechale capital, as an investor, Weardale Lithium is not the only investment which they can exit. For e.g. they bought shares in Future Biogas Group Ltd for £11,600 in 2010/11 and sold for £218,000 in 2023. Did even better exits for Little Chef and Hawksmoor restaurants. Marechale capital's 78% shares are in AIM securities (i.e. public hands).

Marechale capital holds 8% in Founders shares and Options (2022 options exercisable at either exit by Weardale Lithium or £3. 2022 options exercisable at either exit by Weardale Lithium or £5.5). This the only exposure, we public has to the private company Weardale Lithium.

It is possible that with this major milestone achieved by Weardale Lithium, Marechale capital may exit this investment and sell onwards to private investors, thus creating shareholder value. Or hold on to Weardale Lithium for a bigger exit later.

In anycase, a medium term hold now for gold. https://marechalecapital.com/about/

Nissan/Honda may follow the same path. Partnerships and investments will send this sky rocket, and people will forget about the dip today..... Here to the future!!!

https://www.chemanalyst.com/NewsAndDeals/NewsDetails/volkswagen-invests-48-million-in-canadian-lithium-miner-secures-supply-for-ev-battery-34110

It wont be 2 years; hopefully will be early 2026.

https://www.chemanalyst.com/NewsAndDeals/NewsDetails/kbr-to-support-weardale-lithium-uk-demonstration-plant-for-sustainable-lithium-34262